Quantumpharm Inc., known as Xtalpi Inc., announced receiving $51 million up front from a potential $5.99 billion deal with ...

A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at ...

With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, ...

The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments ...

The U.S. Federal Trade Commission (FTC) reported Aug. 6 that it will try to block Edwards Lifesciences Corp.’s proposed ...

Location, location, location. While location is as important in manufacturing as it is in buying a home, it could become even ...

A federal appeals court opened the door Aug. 6 for an amended class-action lawsuit alleging that Astrazeneca plc, Eli Lilly ...

Innogen Pharmaceutical Group announced an $86 million IPO on the Hong Kong Stock Exchange that will see the company advance its lead product, Diabegone (efsubaglutide alfa), an ultra-long-acting ...

Rivo Bio Inc. has disclosed compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia and anxiety disorders.

Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has identified drug-conjugates comprising a radionuclide-labeled molecular probe linked to ligand targeting fibroblast activation protein α ...

Suzhou Raymon Pharmaceuticals Co. Ltd. has patented compounds reported to be useful for the treatment of ocular hypertension.

Hefei Institutes of Physical Science Chinese Academy of Sciences has synthesized phosphoglycerate kinase 1 (PGK1) inhibitors reported to be useful for the treatment of inflammatory bowel disease.